Introduction
In recent years, the application of molecular techniques to the study of human subjects has resulted in a virtual explosion of medical genetic information. This information has greatly expanded our understanding of disease and the mechanisms that cause them. One example is the molecular dissection of the Charcot-MarieTooth (CMT) peripheral neuropathy phenotype. The study of CMT has (i) revealed large DNA rearrangements as a frequent mutation mechanism, (ii) illuminated the importance of gene dosage as a mechanism, (iii) conceptually fused the seemingly disparate categories of Mendelian disorders and chromosomal syndromes, and (iv) illustrated that both allelic variations and locus heterogeneity could be responsible for a spectrum of clinical phenotypes which may include entities thought to be environmental or acquired. This (2) in Cambridge, England independently described the disorder of the peripheral nerves that leads to distal muscle atrophy and weakness that now bears their names. Each recognized the hereditary nature of the disease by pointing to the more frequent occurrence in siblings and observing the disorder in multiple generations in one family. Their observations were reported decades before Mendel's laws were rediscovered. In 1895 Dejerine and Sottas described a more severe neuropathy (3) , the Dejerine-Sottas syndrome (DSS), which was thought then to be clinically distinct from CMT.
In 1939 Allan (3) (8) (9) (10) . The molecular mechanism responsible for the CMT1A duplication is an unequal crossing-over event mediated by the homologous CMTlA-REP repeats. The proposed mechanism predicted a reciprocal recombination product resulting in a 1.5 Mb deletion (10) . This was subsequently shown to be associated with the clinically distinct demyelinating peripheral neuropathy known as hereditary neuropathy with liability to pressure palsies (HNPP) (11, 12) .
Gene Dosage as a Mechanism for Disease Several mechanisms were proposed to explain how the CMT1A duplication might affect a "CMT1 gene." These included (i) gene interruption at the duplication junction (most favored by this author), (ii) a position effect, and (iii) a gene dosage effect due to a dosage-sensitive gene located within the duplicated region. The identification of large, cytogenetically visible chromosomal duplications of chromosome 17p that contained the CMT1A locus in patients whose phenotype included slowed motor NCV supported the gene dosage model (13, 14) (Fig. 1) .
The PMP22 gene encoding peripheral myelin protein 22, which is mutated in the mouse models for human demyelinating neuropathies, Trembler and Trembler' (15, 16) , was shown to map within the 1.5 Mb CMT1A duplication/ HNPP deletion region (17) (18) (19) (20) . The absence of PMP22 point mutation in CMT1A duplication patients further supported a gene dosage model (21) . Rare demyelinating neuropathy patients without the CMT1A duplication were found to have PMP22 point mutations, which are usually associated with a more severe CMT1 phenotype than observed with duplication (22,2 3). PMP22 point mutations were also identified in patients with DSS (24) . To underscore a PMP22-specific dosage effect, increased levels of PMP22 mRNA were found in biopsied peripheral nerves of patients with the CMT1A duplication (25) . Furthermore, multiple transgenic animals that overexpress wild-type PMP22 (26) (27) (28) , and a PMP22 knockout mouse heterozygous for a PMP22 null allele (29, 30) , recapitulated the phenotypic properties of the human demyelinating peripheral neuropathies. Thus, substantial evidence supports the notion that PMP22 is the dosagesensitive gene responsible for the demyelinating phenotype in patients with CMT1A duplication as well as HNPP deletion. This dosage effect is manifested by either trisomic overexpression in CMT1A or monosomic underexpression in HNPP (31, 32) .
Bridging the Gap between Chromosomal Syndromes and Mendelian Disorders
Traditionally, disorders that segregate as Mendelian traits have been believed to result from mutation in single genes. In contrast, chromosomal syndromes have been thought to result from effects of many genes within or flanking the region of chromosomal abnormality. Down syndrome associated with trisomy 21 is the most common genetic condition, and yet it has no mutant genes; however, a distinct clinical phenotype is observed.
Although the potential effects of gene dosage imbalance in chromosomal syndromes had already been appreciated (33) To date, at least seven loci have been associated with a CMTI phenotype, yet 70-90% of all patients have the CMT1A duplication (43). These observations suggest that duplication may be ten times or more likely to cause CMT1 than other mutational mechanisms. Furthermore, CMT1 is one of the most common inherited disorders with an estimated prevalence of 1/2500 individuals. One study estimates that 10% of the CMT1A duplication cases result from de novo events (44) , suggesting a mutation frequency on the order of 10-4. This is 2 to 4 orders of magnitude greater than the spontaneous mutation frequency usually associated with single-gene disorders.
A Recombination Hotspot Associated with Reciprocal Homologous Recombination
The CMTIA-REP repeats flanking the CMT1A duplication/HNPP deletion (45) are -99% identical across a 24,011 bp region. This provides a substantial region of homology for crossover events to occur, yet the majority of crossover events resulting in these DNA rearrangements occur within an approximately 1.7 Kb region (46, 47) . Analysis of the DNA sequence surrounding the crossover hotspot region reveals no significant increase in sequence identity between the proximal and distal CMT1A-REPs when compared with surrounding sequence (46) . These data suggest that some other signal must be present at or near the site of strand exchange to generate the hotspot. Intriguingly, a mariner transposon-like element, termed MITE, maps near the hotspot (46) . We have proposed that MITE may stimulate homologous recombination between CMT1A-REPs by providing a target for double-strand breaks (46) (Fig. 2) . The analysis of the DNA sequence of the recombinant CMTIA-REP in HNPP patients reveals homologous recombination products consistent with a double-strand break model (48 24 Kb of -99% homology for recombination mediated repair, and (3) the hotspot reflecting resolution of the Holliday junction.
Genome Evolution and Consequences of DNA Rearrangements in the CMT1A/HNPP Region The nucleotide sequence of CMTlA-REP has revealed one other coding exon in addition to that for the putative transposase of MITE. This exon is part of the COX1O gene encoding heme A: farnesyltransferase which farnesylates the heme A moiety incorporated into cytochrome oxidase (45) . The human COXIO gene was cloned by human cDNA complementation of a cytochrome oxidase-deficient yeast but was never mapped in the human genome. Subsequent analysis revealed that the entire COX10 gene spans the distal CMTlA-REP (45, 49) . Exon VI of COX10 and 24 Kb of surrounding sequence appear to have been duplicated during genome evolution, at a time of divergence between gorilla and chimpanzees (45, 50) , as there are two copies present in chimpanzees and only one in gorilla, and copied 1.5 Mb proximally on chromosome 17p to yield the proximal CMTIA-REP (Fig. 3) . Thus, the HNPP deletion results in one null allele of COX10 (45) . These findings suggest a further complexity to the consequences of DNA tional mechanism in demyelinating peripheral neuropathy. However, this mechanism does not constitute a mutation hotspot in these three genes that is significantly different from other disease-associated genes (51) . Mutations in MPZ and PMP22 have been identified in patients with the related peripheral neuropathy Dejerine-Sottas syndrome, while MPZ mutations have also been observed in patients with congenital hypomyelination (Fig. 4) . The crystal structure of the extracellular domain of PO has recently been determined (52) . This information, in conjunction with natural mutations observed in demyelinating neuropathy patients, has enabled attempts at genotype/phenotype correlations (53) . Such 
What Does It Mean?
The identification of the CMT1A duplication suggests that other clinical phenotypes may result from submicroscopic DNA rearrangements as opposed to mutations within a gene classically thought of for Mendelian diseases. These rearrangements may reflect structural features of the human genome. The mutation frequencies for DNA rearrangements, and thus de novo mutation in sporadic cases, may be quite high when compared with point mutations. Since these rearrangements may reflect intrinsic structural properties of the genome, the mutation and thus the disease frequency may be similar in different populations.
The high frequency of new mutations suggests that the disease prevalence could be increasing unless reversions are in equilibrium. After the CMT1A duplication occurs, the 1.5 Mb duplicated segment of the genome provides an even larger region for homologous recombination and reversion of the duplication mutation. At least one such case has been suggested by the identification of a patient mosaic for the CMT1A duplication who displayed a milder phenotype than that in the affected parent with the duplication (54, 55) . However, if this were occurring to a significant extent, one might expect to observe segregation distortion, or less than the expected 50% affected individuals, in large autosomal dominant pedigrees.
The CMT1A duplication frequency also likely reflects the recombination hotspot in CMTIA-REP. Whether DNA transposons such as MITE or other mariner-like elements (MLEs) are involved in initiating double strand breaks that stimulate homologous recombination events elsewhere in the human genome remains to be determined.
DNA duplications can be quite large since there is no net loss of genetic information. Given the potential for large size, a duplication may encompass several genes, but it appears from studies of CMT1A and HNPP that only a subset of genes are dosage-sensitive. The PMP22 dosage phenomenon also suggests that the stoichiometry of this protein is important in maintaining normal myelin structure and function. The finding of only one dosage-sensitive gene in a relatively large 1.5 Mb genomic region suggests that the phenotypic manifestations of chromosomal aneuploidy syndromes may represent the effects of a small subset of dosage-sensitive genes. Furthermore, the identification of specific clinical features that can sometimes be found as dominant traits (e.g., syndactyly, brachydactyly, microcornea, etc.) in patients with cytogenetically visible duplications may suggest a potential localization for a dosage-sensitive gene associated with the trait present within the region of segmental aneuploidy.
In summary, there recently has been remarkable progress in elucidating the molecular genetic bases of inherited peripheral neuropathies. These investigations confirm the long-held suspicion that inherited peripheral neuropathies are the clinical manifestations of peripheral nerve dysfunction resulting from abnormalities in Schwann cells and their myelin sheath. These studies have also revealed much about the biology and structure of the peripheral nerve and uncovered novel genetic mechanisms. In addition, the new molecular knowledge has ramifications for patient care. The findings provide the clinician with diagnostic tools to enable a precise and secure diagnosis (56) (57) (58) , enable accurate recurrence risk estimates, and provide prognostic information (59) and the potential to design rational therapeutic approaches. However, perhaps most importantly, genetic findings in this group of disorders has widespread implications for human genetics and the molecular medicine of other disease phenotypes.
